US OptionsDetailed Quotes

PLUR240920P2500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Jul 26 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jul 18 01:33
    NEWS
    $Pluri Inc(PLUR.US)$ $
    Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
    Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division.
    PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment.
    This collaboration leverages Pluri's 47,000 square foot GMP cell production facility a...
    Trytosaveabit
    Trytosaveabit
    Jun 6 05:52
    Update
    $Pluri Inc(PLUR.US)$ Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
    Benzinga· just
    The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
    Trytosaveabit
    Trytosaveabit
    May 20 06:13
    Hmm? Update!
    $Pluri Inc(PLUR.US)$ Benzinga· 2 mins ago
    Pluri Collaborated With Wilk Technologies To Develop Human Breast Milk-derived Food Production On A Commercial Scale
    Jaguar8
    Jaguar8
    May 2 06:06
    $Pluri Inc(PLUR.US)$
    NEWS
    Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
    Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 ...
    Trytosaveabit
    Trytosaveabit
    Apr 17 06:03
    Update
    $Pluri Inc(PLUR.US)$ Pluri Inc: on April 15, Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2)
Read more